Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 1
---
wood has proposed removing STAAR board members and installing its            
 own slate of directors, all without offering any premium or alternative transaction to stockholders. 
 This effort, in Alcon’s view, risks disenfranchising the broader stockholder base and                
 undermining the value-maximizing opportunity currently on the table.                                 |

| · | Alcon                                                                                            
 continues to urge the STAAR Board of Directors to accept its offer to amend the merger agreement 
 to allow for an unencumbered go-shop period, which Alcon believes will give further assurance    
 that the Alcon merger represents the best path forward for STAAR stockholders.                   |

Alcon’s investor discussion materials are available through
Alcon’s investor relations portal at .

Additional Information About the Merger and Where to Find It

This press release relates to the proposed transaction involving STAAR.
In connection with the proposed transaction, STAAR has filed relevant materials with the U.S. Securities and Exchange Commission (the
“SEC”), including STAAR’s definitive proxy statement on Schedule 14A (the “Proxy Statement”), on September
16, 2025. The Proxy Statement was first sent to STAAR stockholders on September 16, 2025. This press release is not a substitute for
the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the proposed
transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH
THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION WITH THE PROPOSED TRANSACTION
WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders
will be able to obtain the documents (when available) free of charge at the SEC’s website, www.sec.gov, or by visiting STAAR’s
investor relations website, https://investors.staar.com.

Comparable transactions based on U.S. cash-only MedTech deals announced since 2015 with deal value above $500 million.

1/3

No Offer or Solicitation

This press release is for informational purposes only and is not intended
to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise
acquire, subscribe for, sell